Clinical trials
Diffuse Large B Cell Lymphoma clinical trials
Below are recruiting diffuse large b cell lymphoma clinical trials, each written for real people, not researchers. We’re tracking 376 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07538635RecruitingPhase 2
CAR-T cells plus stem cell transplant for aggressive lymphoma
This trial tests a two-step treatment for patients with an aggressive type of blood cancer (large B-cell lymphoma) that has come back or didn't respond well to standard therapy. You'll receive a stem cell transplant followed by CAR-T cells—specially engineered immune cells designed to fight cancer.
Hangzhou, ZhengjiangAges 18 years+ - NCT07528352RecruitingPhase 1
Radiation Plus Antibody Therapy for Difficult-to-Treat Lymphoma
This trial tests a combination of radiation therapy to specific tumor sites followed by a bispecific antibody (a type of immunotherapy that targets cancer cells). It's designed for people with diffuse large B-cell lymphoma that has not responded to or has come back after at least two prior treatments.
Salt Lake City, UtahAges 18 years+ - NCT06755775Recruiting
PET scan to predict immunotherapy success in DLBCL
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
ShanghaiAges 18 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+ - NCT07523737RecruitingPhase 2
Combination drug trial for relapsed brain lymphoma
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07507318RecruitingPhase 2
Low-dose chemo to prevent relapse in high-risk DLBCL patients
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06774326Recruiting
Spectral CT to check for heart damage from lymphoma treatment
This study uses a special type of CT scan called spectral CT to see if chemotherapy drugs called anthracyclines can cause heart damage in people with certain lymphomas. The goal is to catch any heart problems early by imaging the heart before, during, and after treatment.
BolognaAges 18 years+ - NCT07473167RecruitingPhase 1/Phase 2
Study of TC011 for large B-cell lymphoma that has not responded to treatment
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Seoul, SeoulAges 19 years+ - NCT07478848RecruitingPhase 1
Radiation, Vancomycin, and CAR-T for B-cell lymphoma
This trial tests whether giving radiation and an oral antibiotic (vancomycin) before CAR-T therapy helps treat B-cell lymphoma more effectively. It is for people who are already scheduled to receive CAR-T treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06782789Recruiting
Study of Tafasitamab and Lenalidomide for aggressive B-cell lymphoma
This study looks back at medical records of people with relapsed or refractory diffuse large B-cell lymphoma who received a combination of two drugs (tafasitamab and lenalidomide) through a special access program. The goal is to learn how well the treatment worked and what side effects occurred.
Bologna, BolognaAges 18 years+ - NCT06796517Recruiting
Immunotherapy for relapsed or refractory lymphoma
This trial tests immunotherapy for people with certain types of lymphoma (diffuse large B cell, primary mediastinal, high grade, or Burkitt) that came back or didn't respond to previous treatment. It aims to see if a new immune-based approach can help.
SeoulAges 19–74 - NCT07451054RecruitingPhase 1
Stem cells plus CAR T-cells for lymphoma
This trial tests a new treatment that combines your own stem cells with special immune cells (CAR T-cells) that target a marker called CD45 on lymphoma cells. It may help people whose lymphoma has not responded to multiple prior therapies.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07451652RecruitingPhase 2
Low dose epcoritamab plus chemotherapy for relapsed lymphoma
This trial tests a combination of a lower dose of the immunotherapy drug epcoritamab with standard chemotherapy (GemOx) for people with a type of lymphoma called DLBCL that has come back or not responded to previous treatment. The goal is to see if this combination can help get the lymphoma under control before a stem cell transplant (using your own cells).
Monterrey, Nuevo LeónAges 18–65 - NCT07443514Recruiting
Thinking and memory in people with DLBCL
This study looks at how thinking and memory may be affected in people newly diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who are about to start a common chemotherapy regimen known as R-CHOP. It also includes a comparison group of healthy relatives. The goal is to understand how treatment may affect cognitive function over time.
LjubljanaAges 18 years+ - NCT06464861RecruitingPhase 1
Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT07424833RecruitingPhase 1
Study of APG-3288 for Relapsed/Refractory Blood Cancers
This trial is testing a new drug called APG-3288 for people with certain relapsed or treatment-resistant blood cancers (like CLL/SLL, DLBCL, MCL, WM, MZL, or FL). You may qualify if you've tried at least 2 prior treatments and are looking for a new option.
Los Angeles, CaliforniaAges 18 years+ - NCT07409428RecruitingPhase 3
Study of HMPL-760 plus R-GemOx for relapsed or refractory DLBCL
This trial tests an experimental drug called HMPL-760 combined with a standard chemo-immunotherapy regimen (R-GemOx) for people whose diffuse large B-cell lymphoma (DLBCL) has come back or stopped responding to treatment. The goal is to see if adding HMPL-760 works better than the standard approach alone.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diffuse large b cell lymphoma?
- Yes. Clin2 currently lists 376 recruiting diffuse large b cell lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diffuse large b cell lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diffuse large b cell lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Refractory Diffuse Large B-Cell Lymphoma
- Recurrent Diffuse Large B-Cell Lymphoma
- Diffuse Large B Cell Lymphoma Relapsed
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
- Large B-cell Lymphoma
- Primary Mediastinal Large B Cell Lymphoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.